V-Fend ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis1

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-005799-41-GB
(EUCTR)
04/10/201221/08/2012Azole Therapy in Cystic Fibrosis (ATCF)Azole Therapy in Cystic Fibrosis (ATCF) : Efficacy of itraconazole and ofvoriconazole in patients with cystic fibrosis and presenting withpersistent positive sputums for Aspergillus - Azole Therapy in Cystic Fibrosis (ATCF) Cystic fibrosis
MedDRA version: 14.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 14.1;Level: HLT;Classification code 10003486;Term: Aspergillus infections;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: SPORANOX
Product Name: Sporanox 10 mg/ml Oral Solution
INN or Proposed INN: ITRACONAZOLE
Other descriptive name: SPORANOX
Trade Name: V-Fend
Product Name: VFEND 40 mg/ml powder for oral suspension
INN or Proposed INN: voriconazole
Other descriptive name: Vfend
CHU de Rennes (Rennes University Hospital Centre)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150United Kingdom